Sangamo Biosciences, Inc. (SGMO) Posts Q2 EPS Loss of $0.20, Releases FY11 Sales Guidance
Sangamo Biosciences, Inc. (NASDAQ: SGMO) reported Q2 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.65 million.
Sangamo Biosciences, Inc. sees FY2011 revenue of $10-$12 million, versus the consensus of $11.03 million.
Sangamo Biosciences, Inc. sees FY2011 revenue of $10-$12 million, versus the consensus of $11.03 million.